CSIMarket
Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 

Integrated Biopharma Inc Growth Comparisons

Select each growth Category to receive further Information



INBP Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) -15.96% 23.1% 12.84% 18.89%
Q / Q Revenue Growth (Q3 MRQ) -25.25% 4.15% 1.39% 3.32%
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 8.14% 54.57% 18.59% %
Seq. Revenue Growth (for 12 months ending Q3 TTM) -3.81% 5.49% 3.25% 4.16%
Revenue 5 Year Average Growth 8.53% 8.66% 9.22% 7.77%
Expected Revenue Growth (Y/Y) - - 1.89% 0.84%


INBP's Growth Comparisons in I. Quarter 2021




Integrated Biopharma Inc's sharp decrease of -15.96% in sales in the first quarter from the same quarter a year ago, those results deviated strongly from rising Revenue in Biotechnology & Pharmaceuticals industry with 23.1%, and underperformed the 12.84% Revenue improvement in the Healthcare sector. Comparing first quarter, sales Integrated Biopharma Inc was trailing overall market not just Biotechnology & Pharmaceuticals industry.

Top-line fell by -25.25% from the forth quarter results. Comparing the annual growth, sales of 8.53% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2021 financial results, average yearly sales growth is 7.77%. Integrated Biopharma Inc grew faster than the market.


Growth Rates of INBP's Income in the first quarter 2021


INBP Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) -61.23% 72.24% 71.27% 57.5%
Seq. Operating Income Change (Q3 MRQ) -55.41% 8.62% 16.9% 7.64%
Y / Y Operating Income Growth (Q3 TTM) 13.23% 99.81% 58.31% 46.8%
Seq. Operating Income Growth (Q3 TTM) -15.98% 14.47% 16.47% 11.63%
Operating Income 5 Year Avg. Change 22.3% -10.18% 2.29% 8.46%


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) -50.43% 175.3% 125.85% 62.76%
Seq. Income from Cont. Ops. Change (Q3 MRQ) -88.55% 35.52% 28.59% 2.41%
Y / Y Income from Cont. Ops. Change (Q3 TTM) 54.81% 98.35% 66.89% 71.68%
Seq. Income from Cont. Ops. Change (Q3 TTM) -6.55% 30.24% 26.04% 11.8%
Income from Cont. Ops. 5 Year Avg. Change 52.93% -22.49% 1.79% 1.07%

INBP Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) -50.43% 182.03% 126.61% 63.56%
Q / Q Net Income Growth (Q3 MRQ) -88.55% 35.65% 27.74% -2.81%
Y / Y Net Income Change (Q3 TTM) 54.81% 94.39% 69.36% 73.25%
Seq. Net Income Change (Q3 TTM) -6.55% 29.13% 26.29% 11.83%
Net Income 5 Year Avg. Growth 52.93% -22.23% 2.24% 1.44%

INBP's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) -50% 161.85% 125.85% 62.76%
Seq. EPS from Cont. Ops. Change (Q3 MRQ) -86.78% 35.87% 28.59% 2.41%
Y / Y EPS from Cont. Ops. Change (Q3 TTM) 53.03% - - -
Seq. EPS from Cont. Ops. Change (Q3 TTM) -7.37% - 0% 99.38%
EPS from Cont. Ops. 5 Year Avg. Growth 40.11% -42.42% 1.79% 1.07%



INBP EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) -33.33% 168.25% 126.61% 1.07%
Q / Q EPS Net Growth (Q3 MRQ) -85.93% 36% 27.74% -2.81%
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 29343.12%
Seq. EPS Net Change (for 12 months ending Q3 TTM) -3.97% - - 99.39%
EPS Net 5 Year Avg. Change 37.97% -22.23% 2.24% 1.44%
Expected EPS Growth (Y/Y) - - 123.59% 14.32%



Integrated Biopharma Inc's EPS were sliced by -33.33% in the first quarter from the same quarter a year ago, to $ 0.02, while income per share in Biotechnology & Pharmaceuticals industry grew by 168.25%, and underperformed the 126.61% EPS surge in the Healthcare sector. Although both Biotechnology & Pharmaceuticals industry and Healthcare sector posted higher gains than 63.56% overall market increase, Integrated Biopharma Inc was trailing overall market in the first quarter.

Bottom-line fell by -85.93% from the forth quarter results. Comparing the annual growth, income per share of 37.97% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2021 earnings, average yearly income per share growth is 1.44%. Integrated Biopharma Inc grew faster than the market.

INBP Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 9.54% 29.85% 44.89% 110.09%
Seq. Free Cash Flow Change (Q3 MRQ) 195.08% 12.82% 32.22% 12.35%
Y / Y Free Cash Flow Change (Q3 TTM) 105.66% 48.38% 32.12% 18.13%
Seq. Free Cash Flow Change (Q3 TTM) 6% 6.23% 8.86% 13.3%
Free Cash Flow 5 Year Avg. Change - 0.83% 13.16% 18.39%

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - -51.59% -17.28% -
Seq. Net Cash Flow Change (Q3 MRQ) - 233.69% 82.58% -
Y / Y Net Cash Flow Change (Q3 TTM) - - -89.64% -70.78%
Seq. Net Cash Flow Change (Q3 TTM) - -76.71% -57.46% 230.07%
Net Cash Flow 5 Year Avg. Change - - 41.15% 124.7%

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 147.17% -16.13% -13.61% 13.66%
Seq. Capital Expenditures Change (Q3 MRQ) -9.66% 10.39% 3.58% 8.81%
Y / Y Capital Expenditures Change (Q3 TTM) 78.47% 27.12% 10.26% 6.15%
Seq. Capital Expenditures Change (Q3 TTM) 26.44% -3.74% -1.08% 1.27%
Capital Expenditures 5 Year Avg. Change - 986.28% 273.59% 86.95%

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 





       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

LEAT's Profile

Stock Price

LEAT's Financials

Business Description

Fundamentals

Charts & Quotes

LEAT's News

Suppliers

LEAT's Competitors

Customers & Markets

Economic Indicators

LEAT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071